Document Detail


Lanreotide for the treatment of acromegaly.
MedLine Citation:
PMID:  19533047     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Lanreotide is an eight-amino acid peptide, which is an analog of the native somatostatin peptide, physiological inhibitor of growth hormone (GH). The drug shows high binding affinity for somatostatin receptors, SSTR2 and SSTR5, which is the primary mechanism considered to be responsible for decreasing GH secretion and GH cell proliferation in acromegaly. Two different formulations of lanreotide are currently available: lanreotide slow release, which requires intramuscular injection every 7-14 days, and lanreotide autogel, which requires deep subcutaneous injection every 4-8 weeks. Several studies have been published to date on the use of lanreotide in acromegaly. Antisecretory efficacy has been reported in 35%-70% of cases; this huge variability is probably explained by different indications (eg, primary or adjunctive postsurgical treatment), or the fact that some studies were based on patients known to be responders to somatostatin analogs. As a primary treatment, antisecretory efficacy was very similar, confirming the possibility of lanreotide as an option in cases of unsuccessful surgery, contraindication, or surgery refusal. Lanreotide also has antitumoral effects as it induces a decrease in tumor volume of [Symbol: see text]25% in 30%-70% of patients. This could be beneficial before transsphenoidal surgery, as a pretreatment, to decrease tumor volume and ease surgery; however, to date, advantages in terms of final remission or uncured status remain a matter of debate. Side effects are rare; the most frequent being gastrointestinal discomfort and increased risk of gallstone formation, and glucose metabolism modifications. Comparison with the other somatostatin analog, octreotide, tends to show identical levels of efficacy between both drugs. Lanreotide thus seems to be an effective treatment in acromegaly. To date, however, lanreotide is still considered as only suspending GH secretion, thus requiring prolonged and costly treatment.
Authors:
F Castinetti; A Saveanu; I Morange; T Brue
Related Documents :
165277 - Tall girls: a survey of 15 years of management and treatment.
23935977 - A novel approach to accounting for loss to follow-up when estimating the relationship b...
17664197 - Cardiac and pericardial echinococcosis: report of 15 cases.
23013507 - Survival rates of mares and foals and postoperative complications and fertility of mare...
12888077 - Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema.
17468547 - Usefulness of the comprehensive geriatric assessment in older patients with upper gastr...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2009-06-16
Journal Detail:
Title:  Advances in therapy     Volume:  26     ISSN:  0741-238X     ISO Abbreviation:  Adv Ther     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-07-07     Completed Date:  2009-12-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  600-12     Citation Subset:  T    
Affiliation:
Department of Endocrinology, Université de la Méditerranée, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acromegaly / drug therapy*
Antineoplastic Agents / therapeutic use
Human Growth Hormone / drug effects
Humans
Peptides, Cyclic / adverse effects,  therapeutic use*
Pituitary Neoplasms / drug therapy
Somatostatin / adverse effects,  analogs & derivatives*,  therapeutic use
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Peptides, Cyclic; 118992-92-0/lanreotide; 12629-01-5/Human Growth Hormone; 51110-01-1/Somatostatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Performance characteristics of a sliding-scale hypertonic saline infusion protocol for the treatment...
Next Document:  Urinary iodine excretion in German adults in 2005 meets WHO target